Tralokinumab for eczema with genital symptoms
Treatments studied
Part of Genetic & congenital, Immune system & allergy, Skin clinical trials.
This trial tests if tralokinumab, a drug already approved for moderate-to-severe eczema, helps people who also have eczema in the genital area. It aims to understand how well the drug works for this specific symptom.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have moderate to severe eczema that also affects your genital area.
- Your doctor has already decided to start you on tralokinumab as part of your normal care.
- You are able to give informed consent and follow the study instructions.
- You are not pregnant or nursing, and you are not taking part in any other study with experimental treatments.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses a special microscope to take close-up pictures of your skin before and after starting tralokinumab, a biologic medication for moderate-to-severe eczema (atopic dermatitis). Researchers want to understand how this treatment changes your skin at a microscopic level.
This study tracks pregnancy and baby outcomes in people who have been pregnant while taking tralokinumab, a medication for eczema. It compares those outcomes to other eczema treatment groups to help doctors understand potential risks or reassuring effects.
This study tests an investigational shot (tralokinumab) plus a steroid cream for children with moderate-to-severe eczema that hasn't been controlled by creams alone. It aims to see if the combination is safe and works better than the cream alone.
This study tests whether combining two drugs, dupilumab and tofacitinib, works better for moderate to severe eczema in adults than either alone. It may help people whose eczema is not well controlled with standard treatments.
This trial tests whether tildrakizumab, a biologic medicine, can help people with psoriasis that affects their genital area. It aims to see if the drug reduces symptoms like redness and scaling in those sensitive regions.
This trial tests a new medication for people with moderate-to-severe eczema. It aims to see if the treatment is safe and effective for reducing symptoms.
Hear when a new Atopic Dermatitis (Moderate-to-severe) Involving the Genital Region trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.